Investigation of the Drug Dimethoxbenzylidene Anabaseine in Treating Schizophrenia Patients

Completed · Phase 1 · Has a placebo group

Conditions studied: Schizophrenia, Psychotic Disorders

In brief

This study will determine the effectiveness of a drug, dimethoxbenzylidene anabaseine, in producing beneficial effects similar to that of nicotine in individuals with schizophrenia.

Key facts

Study ID

NCT00255918

Run by

University of Colorado, Denver

People needed

12

Starts

2004-03-01

Expected to finish

2005-10-01

Last updated by the study team

2015-07-01

Who can join

Age: 18 and older, up to 60. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of schizophrenia

You may not qualify if…

• History of cardiovascular illness or neurological illness other than schizophrenia
• Current substance abuse, including nicotine
• History of clozapine use

Where it is running

• University of Colorado General Clinical Research Center — Denver, Colorado, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.